News
COPD Foundation appoints Lawrence Stern, Michael Mayer to board of directors
Business Wire
WASHINGTON — The COPD Foundation (COPDF) today announced the appointment of two new members to its Board of Directors: Lawrence Stern, the former Chairman and CEO of Talecris Biotherapeutics and Michael P. Mayer, co-creator of the Richard H. Scarborough Bronchiectasis Research Consortium and Registry.
“We’re honored to have new members join our Board,” says John W. Walsh, president of the COPD Foundation. “Larry’s extensive experience in the healthcare industry, active role in healthcare reform initiatives and commitment to improving the lives of individuals affected by COPD bring a valuable dimension to the Board. Mike brings considerable business and fundraising experience, as well as a passion and commitment to expand activities supported by the Richard H. Scarborough Bronchiectasis Research Registry to extend his father-in-law’s legacy to cure bronchiectasis.”
